Painchek [ASX:PCK] about to be the next breakout stock? Part 3 of 3.

The InsideMarket Private Fund owns shares in Painchek at the time of publishing this post. We have not received any payment from the company for this coverage. More disclosure at end of this post.

Painchek {ASX:PCK] is a business on the brink of exponential growth, according to its CEO Philip Daffas.

In the final part of my series on the pain management app Painchek, Philip Daffas explains how the leading American aged care facilities are literally calling him, asking when will the app be available in the US.

We also discuss in detail, the infant version of Painchek's, technology and how it may alter the current clinical trial, effectively shortening the process.

Let me know what you think of Painchek (ASX:PCK) or if you'd like me to look at any other tech companies.

PART 2

PART 1

The InsideMarket Private Fund owns shares in Painchek at the time of publishing this post. We have not received any payment from the company for this coverage. Disruptive technology stocks should be considered very speculative, high-risk, and extremely volatile. There are significant risks inherent in developing new technologies that are not discussed here. You should always seek professional advice before considering any share purchase or sale. Please read our full disclaimer.